125 related articles for article (PubMed ID: 23862197)
1. [A posteriori biological demonstration of the concept of hormone-radiotherapy combination in cancer of the prostate].
Magné N
Bull Cancer; 2013 May; 100(5):415-6. PubMed ID: 23862197
[No Abstract] [Full Text] [Related]
2. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer--treatment of disseminated disease.
Abi-Aad AS; Opsomer RJ
Acta Urol Belg; 1996 May; 64(2):67-76. PubMed ID: 8701817
[No Abstract] [Full Text] [Related]
4. [Hormone therapy of locally advanced cancer of the prostate validated by several randomized trials].
Mazeron JJ
Bull Cancer; 2011 Feb; 98(2):93-4. PubMed ID: 21591300
[No Abstract] [Full Text] [Related]
5. [Evolution of endocrine therapy for prostate cancer].
Igawa T; Saito Y
Nihon Rinsho; 2000 Jul; 58 Suppl():176-81. PubMed ID: 11022709
[No Abstract] [Full Text] [Related]
6. [Treatment of advanced prostate cancer].
Leisinger HJ; Jichlinski P
Rev Med Suisse Romande; 1999 Jun; 119(6):507-11. PubMed ID: 10422478
[No Abstract] [Full Text] [Related]
7. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-58.
Pitts WR
Eur Urol; 2007 Mar; 51(3):864. PubMed ID: 16860461
[No Abstract] [Full Text] [Related]
8. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
9. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
Pollack A; Horwitz EM
Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
[No Abstract] [Full Text] [Related]
10. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer.
Roach M
Cancer; 2014 Jun; 120(11):1620-9. PubMed ID: 24591080
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer.
Bolla M; Descotes JL; Artignan X; Fourneret P
BJU Int; 2007 Jul; 100 Suppl 2():44-7. PubMed ID: 17594359
[No Abstract] [Full Text] [Related]
12. Hormonal treatment of prostate cancer.
Garnick MB
N Engl J Med; 1999 Mar; 340(10):812-3. PubMed ID: 10075531
[No Abstract] [Full Text] [Related]
13. Recent advances in hormonal therapy for advanced prostate cancer.
Oottamasathien S; Crawford ED
Oncology (Williston Park); 2003 Aug; 17(8):1047-52; discussion 1054-8. PubMed ID: 12966672
[TBL] [Abstract][Full Text] [Related]
14. Prostate surgery follow-up.
Health News; 2000 Jan; 6(1):6. PubMed ID: 11019660
[No Abstract] [Full Text] [Related]
15. Initial therapy of advanced prostate cancer.
Ismail M; Gomella LG
Compr Ther; 1997 Oct; 23(10):649-55. PubMed ID: 9327180
[No Abstract] [Full Text] [Related]
16. Hormone ablation therapy: lightening the load for today's prostate cancer patient.
Matthews PA
Urol Nurs; 2007 Feb; 27 Suppl():3-11. PubMed ID: 17474637
[TBL] [Abstract][Full Text] [Related]
17. Cost comparison of orchiectomy and leuprolide in metastatic prostate cancer.
Bonzani RA; Stricker HJ; Peabody JO; Menon M
J Urol; 1998 Dec; 160(6 Pt 2):2446-9. PubMed ID: 9817400
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with flutamide and castration (orchiectomy or LH-RH agonist) in untreated patients with advanced prostate cancer.
Dupont A; Labrie F; Cusan L; Gomez JL; Tremblay M; Lacourcière Y; Emond J; Monfette G
Recent Results Cancer Res; 1992; 124():43-54. PubMed ID: 1615218
[No Abstract] [Full Text] [Related]
19. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
[TBL] [Abstract][Full Text] [Related]
20. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
Solberg A; Haugen OA; Viset T; Bergh A; Tasdemir I; Ahlgren G; Widmark A; Angelsen A
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):55-61. PubMed ID: 20598453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
